Actionable insights straight to your inbox

Equities logo

Cavitation Technologies, Inc. (CVAT) announces Consulting Agreement With PharmaConsult Ltd.

Cavitation Technologies, Inc. (OTQBB: CVAT) announced that it has a consulting agreement with PharmaConsult Ltd. They will advise Cavitation on the expansion of its patented NANOreactor® technology

Cavitation Technologies, Inc. (OTQBB: CVAT; Berlin: WTC), is pleased to announce that it has entered into a consulting agreement with PharmaConsult Ltd. The agreement calls for PharmaConsult Ltd., to advise Cavitation Technologies, Inc on the strategic expansion of its patented NANOreactor® technology into the pharmaceutical industry in order to improve the delivery of active pharmaceutical ingredients by creating a nano-sized droplets that allow significant absorption rate due to sub-micron particle size. CVAT technology offers ecologically friendly, greener processing technique for the generation of pharmaceutical grade nano emulsions, which improves thermodynamic stability, bioavailability, increased drug solubilization and rapid dissolution after administration.

Roman Gordon, Global Technology Manager commented, “We see PharmaConsult Ltd. as a valuable partner for Cavitation Technologies, Inc to help us enter the field in the pharmaceutical industry. We look forward to working with PharmaConsult Ltd. to accelerate the development of new drug delivery methods and enhance our portfolio of products”.

“We are pleased that Cavitation Technologies, Inc has selected us as their partner. Many drugs currently fail the clinical trial phase due to poor bioavailability and our knowledge in the pharmaceutical industry will allow us to give CVAT the necessary support to help the Company to present their unique patented technology to the pharmaceutical industry” says Dana Rubin, founder of PharmaConsult Ltd.

Cavitation Technologies, Inc develops high-efficiency technologies for processing fluids in various industries and is uniquely positioned to provide their technology to pharmaceutical and medical cannabis industry.

About CTi
Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement and water treatment. As an add-on to its existing neutralization systems, the company’s patented Nano Reactor ® allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.

About PharmaConsult Ltd.
PharmaConsult Ltd. is an independent consulting company which advises mid-sized and start-up pharmaceutical and biotechnology companies. PharmaConsult specializes in guiding startups specifically cannabinoid based therapeutics with regulatory guidance, compliance, and information for the FDA, DEA and other regulatory agencies. PharmaConsult specializes in providing tools that help companies develop a strategic plan to gain a sustainable competitive advantage. They offer support for Generics, Branded Drugs, Biosimilars and Cannabinoid Therapeutics.

In the interest of full disclosure, we call the reader’s attention to the fact that, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

As the markets put the debt ceiling debacle in the rearview mirror, more than a few issues remain open.